Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2026 06:16 ET | Source: ALK Abello

Three-month interim report (Q1) 2026 (unaudited) - English version only

ALK delivers 18% organic revenue growth with operating profit (EBIT) up 22% in Q1 Q1 saw broad-based growth across key categories and regions with sustained, strong momentum in tablet sales in Europe...
May 04, 2026 06:16 ET | Source: ALK Abello

Three-month interim report (Q1) 2026 (unaudited)

ALK delivers 18% organic revenue growth with operating profit (EBIT) up 22% in Q1 Q1 saw broad-based growth across key categories and regions with sustained, strong momentum in tablet sales in Europe...
May 04, 2026 06:09 ET | Source: ALK Abello

ALK opjusterer forventningerne til 2026

Intern viden ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) har i dag annonceret, at forventningerne til helåret er blevet opjusteret. De ændrede forventninger afspejler et stærkt underliggende momentum...
May 04, 2026 06:09 ET | Source: ALK Abello

ALK upgrades its full-year outlook

Inside Information ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the 2026 full-year financial outlook has been upgraded reflecting a strong underlying momentum for tablet sales and...
April 28, 2026 10:14 ET | Source: ALK Abello

Invitation til præsentation af ALK’s regnskab for første kvartal 2026 tirsdag den 5. maj 2026

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) offentliggør delårsrapport for de første tre måneder af 2026 (Q1) om morgenen tirsdag den 5. maj 2026. ALK afholder senere samme dag kl. 13.30 (CEST) en...
April 28, 2026 10:14 ET | Source: ALK Abello

Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first quarter of 2026 in the morning on Tuesday, 5 May 2026. Later on the same day, the company will host a presentation for...
April 20, 2026 08:33 ET | Source: ALK Abello

ALK annoncerer positive fase 2-resultater for tablet til behandling af peanutallergi, som viser tidligt indsættende effekt

Intern viden ALLIANCE fase 2‑studiet demonstrerede proof‑of‑concept efter kun 6 måneders vedligeholdelsesbehandling i en bred patientgruppe bestående af både børn og voksne.Klar dosisafhængig og...
April 20, 2026 08:33 ET | Source: ALK Abello

ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy

Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults.Clear...
April 15, 2026 06:07 ET | Source: ALK Abello

neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Health Canada has approved neffy® 2 mg for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites,...
April 08, 2026 16:37 ET | Source: ALK Abello

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...